Zacks Small Cap Comments on Lantern Pharma FY2024 Earnings

Lantern Pharma Inc. (NASDAQ:LTRN) – Analysts at Zacks Small Cap increased their FY2024 EPS estimates for shares of Lantern Pharma in a research report issued on Tuesday, November 12th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($1.90) for the year, up from their previous forecast of ($2.12). The consensus estimate for Lantern Pharma’s current full-year earnings is ($2.12) per share. Zacks Small Cap also issued estimates for Lantern Pharma’s Q4 2024 earnings at ($0.51) EPS and FY2025 earnings at ($1.86) EPS.

Lantern Pharma Trading Down 1.4 %

Shares of Lantern Pharma stock opened at $3.53 on Thursday. Lantern Pharma has a 12 month low of $3.04 and a 12 month high of $11.99. The stock’s fifty day moving average price is $3.59 and its 200-day moving average price is $4.46. The firm has a market cap of $38.05 million, a P/E ratio of -1.98 and a beta of 1.58.

Institutional Investors Weigh In On Lantern Pharma

Several institutional investors have recently bought and sold shares of LTRN. Dimensional Fund Advisors LP boosted its holdings in shares of Lantern Pharma by 55.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 18,413 shares of the company’s stock valued at $86,000 after acquiring an additional 6,585 shares during the last quarter. Westside Investment Management Inc. acquired a new position in Lantern Pharma in the 2nd quarter valued at $54,000. Tocqueville Asset Management L.P. purchased a new position in Lantern Pharma during the first quarter worth approximately $167,000. Renaissance Technologies LLC raised its stake in Lantern Pharma by 24.5% during the second quarter. Renaissance Technologies LLC now owns 81,800 shares of the company’s stock worth $382,000 after purchasing an additional 16,100 shares during the period. Finally, CM Management LLC lifted its stake in shares of Lantern Pharma by 23.1% in the 2nd quarter. CM Management LLC now owns 80,000 shares of the company’s stock valued at $374,000 after purchasing an additional 15,000 shares during the last quarter. 28.62% of the stock is currently owned by institutional investors and hedge funds.

Lantern Pharma Company Profile

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma.